NAMS in the 13F filings
Newamsterdam Pharma Company · CUSIP N62509109
- Quarter end
- 31 Dec 2025
- the date the book describes
- Filed
- 19 Feb 2026
- latest of these filings; the earliest 10 Feb 2026
- Managers listing it
- 22
- at least, of 95 tracked, among listed positions
- Comparable managers
- 92
- filed both Q3 2025 and Q4 2025; 5 listed it in both
- Shares listed
- 33,784,816
- combined, among listed positions
- Reported value
- $1.2bn
- combined, at the quarter end
Among the 92 comparable managers: 17 buyers (opened or added shares) and 5 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +363,399.
Managers listing NAMS in Q4 2025
22 of 22 holders
Largest increases and reductions, by shares
Increases
- Wellington Management Group LLPexisting position · 5,033,175 shares now+1,013,049
- Fidelity (FMR LLC)existing position · 6,412,984 shares now+877,691
- Citadel Advisors LLCexisting position · 635,247 shares now+428,786
- Jane Street Group LLCnew position · 421,491 shares now+421,491
- Maverick Capital Ltdexisting position · 1,894,226 shares now+389,479
Reductions
- Viking Global Investors LPexisting position · 4,203,567 shares now-2,271,967
- AllianceBernstein LPexisting position · 1,300,875 shares now-840,903
- Woodline Partners LPexisting position · 751,270 shares now-406,597
- Invesco Ltdexisting position · 5,961 shares now-98,715
- T. Rowe Price Associates Incexisting position · 116,258 shares now-22,071
New positions and exits
New (7)
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q4 2022 | 1 | $39m | n.a. | n.a. |
| Q1 2023 | 1 | $53m | n.a. | n.a. |
| Q2 2023 | 1 | $78m | n.a. | n.a. |
| Q3 2023 | 1 | $74m | n.a. | n.a. |
| Q4 2023 | 1 | $90m | 0 | 0 |
| Q1 2024 | 1 | $190m | 0 | 0 |
| Q2 2024 | 2 | $163m | 1 | 0 |
| Q3 2024 | 2 | $153m | 1 | 0 |
| Q4 2024 | 5 | $322m | 4 | 1 |
| Q1 2025 | 5 | $391m | 4 | 0 |
| Q2 2025 | 5 | $376m | 2 | 2 |
| Q3 2025 | 5 | $599m | 2 | 3 |
| Q4 2025 | 8 | $851m | 17 | 5 |
| Q1 2026 | 6 | $820m | 13 | 11 |
| Q2 2026 | 6 | $790m | 21 | 6 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
NAMS and LLY →NAMS and JNJ →NAMS and VRTX →Choose a stock to compare with NAMS →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own NAMS, latest filings →Back to the 13F Explorer →